190 related articles for article (PubMed ID: 37975979)
1. The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review.
El-Andari R; Fialka NM; Kang J; Bozso SJ; Nagendran J; Nagendran J
Am J Cardiovasc Drugs; 2024 Jan; 24(1):55-69. PubMed ID: 37975979
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
Lee HF; Chan YH; Chuang C; Li PR; Yeh YH; Hsiao FC; Peng JR; See LC
Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):301-310. PubMed ID: 36639127
[TBL] [Abstract][Full Text] [Related]
4. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
5. Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases.
Gulsin GS; Graham-Brown MPM; Squire IB; Davies MJ; McCann GP
Heart; 2022 Jan; 108(1):16-21. PubMed ID: 33972360
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
7. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis.
Li M; Yi T; Fan F; Qiu L; Wang Z; Weng H; Ma W; Zhang Y; Huo Y
Cardiovasc Diabetol; 2022 Jul; 21(1):139. PubMed ID: 35879763
[TBL] [Abstract][Full Text] [Related]
8. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
[TBL] [Abstract][Full Text] [Related]
10. Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus.
Kim CH; Hwang IC; Choi HM; Ahn CH; Yoon YE; Cho GY
Int J Cardiol; 2022 Oct; 364():104-111. PubMed ID: 35716949
[TBL] [Abstract][Full Text] [Related]
11. Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Bioenergetic Properties and Cardiorespiratory Fitness: A Special Effect of SGLT2i In Heart Failure?
Farooq M; Jorde UP
Cardiol Rev; 2023 Mar-Apr 01; 31(2):65-69. PubMed ID: 35191660
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
13. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
[TBL] [Abstract][Full Text] [Related]
14. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of sodium glucose cotransporter 2 inhibitors on left ventricular mass in patients with diabetes mellitus.
Kosugi D; Inaba H; Kaido Y; Ito S; Hirobata T; Toyofuku M; Matsuoka T; Inoue G
J Diabetes; 2021 Nov; 13(11):847-856. PubMed ID: 34231959
[TBL] [Abstract][Full Text] [Related]
16. The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction - A systematic review.
Chong JH; Chang WT; Chan JJ; Tan TJY; Chan JWK; Wong M; Wong FY; Chuah CTH
Curr Probl Cardiol; 2024 Mar; 49(3):102372. PubMed ID: 38281354
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review.
Rasalam R; Atherton JJ; Deed G; Molloy-Bland M; Cohen N; Sindone A
ESC Heart Fail; 2021 Oct; 8(5):4093-4118. PubMed ID: 34219407
[TBL] [Abstract][Full Text] [Related]
19. Sodium-Glucose Cotransporter-2 Inhibitors Stabilize Coronary Plaques in Acute Coronary Syndrome With Diabetes Mellitus.
Kurozumi A; Shishido K; Yamashita T; Sato D; Uchida S; Koyama E; Tamaki Y; Hayashi T; Miyashita H; Yokoyama H; Ochiai T; Yamaguchi M; Moriyama N; Tobita K; Matsumoto T; Mizuno S; Yamanaka F; Tanaka Y; Murakami M; Takahashi S; Saito S
Am J Cardiol; 2024 Mar; 214():47-54. PubMed ID: 38215815
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient.
Severino P; D'Amato A; Prosperi S; Costi B; Angotti D; Birtolo LI; Chimenti C; Lavalle C; Maestrini V; Mancone M; Fedele F
Heart Fail Rev; 2023 May; 28(3):709-721. PubMed ID: 34654997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
